Five attributes are essential for emerging biotech companies to thrive and grow in what will be a challenging financing environment for the foreseeable future. These attributes also serve as a proxy for creating long-term, sustainable value.
- Delivering The Next Evolution In Immuno-Oncology
- Start Fast, Finish Fast: How To Complete Projects On Time
- Small Startup Going For A Big Play In Obesity
- A View From The Co-Chair Of Israel’s Biopharma Industry Trade Organization
- Leveraging Fractional Expertise to Drive Project Success and Cost Savings
- Examining The Growth Of Biopharma In Developing Countries
- Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals
- What The Emerging Science Tells Us About Treating Obesity
COMPANIES TO WATCH
-
Companies To Watch: Antiva Biosciences
Antiva Biosciences is exploring a local and global opportunity with a topically administered HPV treatment.
-
A novel small molecule developer aims to shake up the solid tumor treatment landscape.
-
Founded in late 2019, KeifeRx is repurposing oncology drugs for neurodegenerative disorders.
-
Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.
WHERE ARE THEY NOW
-
Where Are They Now? Novo Nordisk
In a few short years, Novo Nordisk has gone from belt-tightening to parachute pants, and is now replaying a GLP-1 competition with Eli Lilly that kicked off with Victoza and Trulicity ten years ago.
-
Where Are They Now? Ono Pharmaceuticals
Ono Pharmaceuticals continues its quest to become a global biopharmaceutical company, after discovering and helping to launch one of the most successful cancer drugs, Opdivo, in the last decade.
-
Where Are They Now? Roivant
"Where Are They Now?" looks back, and forward, at companies and executives previously covered in Life Science Leader magazine.